催化资本顾问公司大幅削减了AstraZeneca的股份,然而分析师却将股票升级为“Buy”。 Catalyst Capital Advisors cut AstraZeneca holdings sharply, yet analysts upgrade stock to "Buy."

AstraZeneca PLC(NASDAQ:AZN)看到催化剂资本顾问有限责任公司将其持有量减少98.8%,出售35 750股,留下价值29 000美元的449股。 AstraZeneca PLC (NASDAQ:AZN) saw Catalyst Capital Advisors LLC reduce its holdings by 98.8%, selling 35,750 shares and leaving 449 shares valued at $29,000. 各种机构投资者调整了他们的利害关系,有些增加了他们的持有量。 Various institutional investors have adjusted their stakes, with some increasing their holdings. 来自德意志银行、摩根斯坦利(Morgan Stanley)和UBS的分析师将AstraZeneca的评级升级为持有、超重和购买, Analysts from Deutsche Bank, Morgan Stanley, and UBS upgraded AstraZeneca’s rating to hold, overweight, and buy, respectively, with a consensus "Buy" rating and a price target of $89.75. 尽管报告收入未达到分析师估计的0.05美元,但该公司宣布每股半年1美元红利,每股收益为2%。 Despite reporting earnings that missed analyst estimates by $0.05, the company announced a semi-annual dividend of $1.03 per share, yielding 2%.